Belsomra vs Dayvigo: Cost, Insurance Coverage, and Access Compared

How Retail Pricing Compares in 2026

At full retail, a 30-day supply of Belsomra (suvorexant 20 mg) runs approximately $480 to $530, while Dayvigo (lemborexant 10 mg) comes in around $380 to $430. Both remain brand-only. No FDA-approved generic exists for either drug because their patent exclusivity windows have not fully expired.

Price differences narrow or vanish once insurance is applied. The real determinant for most patients is formulary tier, not sticker price. Both Merck (Belsomra) and Eisai (Dayvigo) have responded to formulary pressure by offering manufacturer copay assistance programs. Merck's Belsomra savings card reduces copays to as little as $0 for eligible patients with commercial insurance, covering up to $150 per 30-day fill 1. Eisai's Dayvigo copay program similarly targets $0 out-of-pocket for commercially insured patients. Neither program covers Medicare Part D, Medicaid, or other federal program beneficiaries, per the Anti-Kickback Statute restrictions.

For uninsured patients, GoodRx-type discount cards pull Belsomra toward $440 and Dayvigo toward $370. These prices fluctuate by pharmacy and region, but the relative gap stays consistent: Dayvigo runs roughly 10-15% cheaper at cash price across major chain pharmacies.

Insurance Formulary Placement and Prior Authorization

Most commercial plans and Medicare Part D formularies place both drugs on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). The deciding factor is often which manufacturer negotiated a better rebate with a given plan's pharmacy benefit manager. Prior authorization (PA) requirements are common for both, typically requiring documented failure of at least one first-line agent.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline gives a conditional recommendation for both suvorexant and lemborexant in adults with chronic insomnia, placing them alongside other pharmacologic options rather than ranking one above the other. Most insurers use step therapy aligned with this guideline: patients must try cognitive behavioral therapy for insomnia (CBT-I) or a less expensive medication such as generic trazodone or generic zolpidem before the plan approves a DORA [2].

Medicare Part D coverage varies widely. An analysis by the Centers for Medicare & Medicaid Services shows that formulary inclusion for branded sleep medications depends heavily on plan sponsor negotiations. Some Part D plans exclude DORAs entirely, while others cover one but not both. Patients on Medicare who need a DORA often face a coverage gap ("donut hole") cost of several hundred dollars per fill, since manufacturer copay cards cannot be applied to federal program prescriptions 3.

A 2022 retrospective claims analysis found that approximately 42% of DORA prescriptions required PA across commercial plans, and the average time to PA approval was 3 to 5 business days 4. Patients and prescribers should plan for this delay when transitioning from another sleep medication.

Efficacy: What the Clinical Trials Show

No large, published, direct head-to-head randomized trial compares suvorexant to lemborexant. Clinicians rely on indirect comparison across separate key trials, keeping in mind the limitations of cross-trial analysis.

Belsomra (suvorexant): The Herring et al. 2014 trial enrolled 1,021 patients with insomnia disorder in a randomized, double-blind, placebo-controlled study 5. At the 40 mg dose (higher than the FDA-approved maximum of 20 mg), suvorexant improved subjective total sleep time (sTST) by approximately 20 minutes versus placebo at 4 weeks. At the 20 mg dose, improvements in sleep onset latency and wake after sleep onset were statistically significant but more modest. The most common adverse event was next-day somnolence, reported in 7% of patients versus 3% on placebo.

Dayvigo (lemborexant): SUNRISE-1, published in JAMA Network Open (2019), randomized 1,006 adults aged 55 and older to lemborexant 5 mg, 10 mg, or placebo 6. At 30 nights, lemborexant 5 mg reduced latency to persistent sleep (LPS) by 10.5 minutes versus placebo (P<0.001), and lemborexant 10 mg reduced LPS by 12.6 minutes versus placebo (P<0.001). Wake after sleep onset (WASO) improved significantly with both doses. SUNRISE-2 extended these findings to 12 months, confirming sustained efficacy without evidence of tolerance 7.

A network meta-analysis published in the Journal of Clinical Sleep Medicine (2022) compared DORAs with other insomnia medications using Bayesian methods across 154 randomized trials 8. Lemborexant and suvorexant performed similarly on subjective sleep onset latency (SOL), but lemborexant showed a numerical advantage on WASO endpoints. Both DORAs demonstrated lower rates of complex sleep behaviors compared to Z-drugs such as zolpidem and eszopiclone 9, which prompted the FDA to add a boxed warning to Z-drugs in 2019.

Next-Morning Function and Safety

Residual sedation is a practical differentiator. The FDA's initial suvorexant review flagged dose-dependent next-morning driving impairment, which is why the agency approved 10 mg and 20 mg rather than the 30 mg and 40 mg doses Merck originally requested 10. At the approved 20 mg dose, a subset of patients still reported enough morning grogginess to affect alertness.

Lemborexant 5 mg, by contrast, showed no statistically significant impairment on next-morning driving performance in a randomized crossover study using the on-road driving test, the gold standard for sedation measurement 11. At the 10 mg dose, a small but statistically significant impairment appeared in some subjects. This is one reason the FDA set lemborexant's recommended starting dose at 5 mg rather than 10 mg.

For patients whose morning function is a priority (shift workers, those with long commutes, older adults at fall risk), this difference may tilt the risk-benefit analysis toward lemborexant at its lower dose. The Endocrine Society and AASM guidelines do not rank one DORA above the other but recommend individualized dosing based on tolerance and next-day impairment risk [12].

Both drugs carry DEA Schedule IV classification. The abuse liability data from premarketing studies showed low potential for either agent, with subjective "drug liking" scores well below those of zolpidem at equipotent doses 13.

Patient Assistance and Access Programs

Both manufacturers maintain strong access programs because neither drug faces generic competition.

Belsomra (Merck): The Merck Patient Assistance Program provides Belsomra at no cost to qualifying uninsured patients with household incomes at or below 400% of the federal poverty level. Commercially insured patients can use the Belsomra Savings Card. Merck also operates a bridge supply program for patients awaiting PA decisions 14.

Dayvigo (Eisai): The Eisai Patient Assistance Program (EPAP) covers Dayvigo for eligible uninsured or underinsured patients. The Dayvigo Savings Card can reduce copays to $0 with a maximum annual benefit. Eisai's program also supports appeals when a prior authorization is denied 15.

For Medicare Part D beneficiaries in the coverage gap, the Extra Help (Low-Income Subsidy) program through the Social Security Administration can reduce DORA costs substantially. Patients with annual incomes below $22,590 (individual, 2026) may qualify for premium and copay assistance that brings DORA costs under $10 per fill.

Practical Decision Framework: Choosing Between Belsomra and Dayvigo

The choice between these two DORAs usually comes down to four variables: formulary placement, out-of-pocket cost after copay card, morning function needs, and dosing flexibility.

Start with the patient's insurance formulary. If one drug has a lower tier or does not require PA, that drug wins on access speed and cost. If both are on the same tier, Dayvigo's lower retail price gives it a slight edge for patients paying cash or facing coinsurance percentages rather than flat copays.

For patients who need full next-morning alertness, lemborexant 5 mg carries the stronger evidence base on driving performance 11. For patients who tolerate suvorexant 20 mg without morning grogginess, there is no compelling clinical reason to switch.

Switching between the two is straightforward. Both bind the same OX1R and OX2R receptor targets 16. A washout period is not pharmacologically necessary, though most clinicians will cross-taper by starting the new DORA on the night after the last dose of the old one.

The FDA prescribing information for Dayvigo notes that patients switching from another insomnia medication should be monitored for potential withdrawal or rebound insomnia from the discontinued agent, not from the new DORA itself [17].

Older Adults: Special Considerations

Both DORAs have data in older patients, but Dayvigo's key SUNRISE-1 trial specifically enrolled adults aged 55 and older 6. This is a meaningful advantage for clinicians treating geriatric insomnia, where most evidence comes from trials with younger populations.

The American Geriatrics Society (AGS) Beers Criteria lists benzodiazepines, Z-drugs, and antihistamines as potentially inappropriate in older adults due to fall risk, cognitive impairment, and delirium. DORAs are not listed on the Beers Criteria, making them a preferred pharmacologic option when CBT-I alone is insufficient 18.

Suvorexant dose adjustments are not required by age alone per the FDA label, but the 10 mg starting dose is often preferred in older adults because of slower hepatic metabolism. Lemborexant's 5 mg starting dose provides a lower entry point. In SUNRISE-1, the 5 mg dose achieved significant improvements in LPS and WASO in the 55+ population without dose adjustment 6.

A secondary analysis of the SUNRISE trials found that lemborexant did not increase fall rates in adults over age 65 compared to placebo over 12 months 19. This is clinically relevant given that hip fractures from sedative-related falls carry a 20-30% one-year mortality rate in adults over 75 20.

Drug Interactions and Contraindications

Both DORAs are metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) significantly increase exposure to both drugs. The Belsomra label contraindications include use with strong CYP3A4 inhibitors, while the Dayvigo label recommends dose reduction to 5 mg rather than contraindication 17. This gives Dayvigo slightly more flexibility for patients on interacting medications.

Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil, grapefruit juice) also increase DORA levels. Prescribers should check for interactions before initiating either drug. Neither DORA should be used with other CNS depressants, including alcohol, without careful dose consideration and patient counseling 21.

Neither drug is recommended in patients with severe hepatic impairment or narcolepsy. Both are pregnancy category C equivalents under the post-2015 FDA labeling system, with insufficient human data to assess fetal risk.

The Generic Timeline

Belsomra's core patent protection extends through approximately 2029, and Dayvigo's extends through approximately 2032, though pediatric exclusivity extensions could shift these dates. No ANDA (Abbreviated New Drug Application) for a generic version of either drug appears in the FDA's Orange Book as of May 2026 [22].

Until generics arrive, cost competition between these two drugs depends on manufacturer pricing decisions and PBM negotiations. The entry of a third DORA or a generic for an older insomnia drug class can indirectly shift formulary economics.

Patients currently stable on either drug should verify their formulary status each plan year during open enrollment, as tier changes are common when rebate contracts are renegotiated.